Transparent Clinical Trial Matching

Regulators and sponsors demand transparency in patient selection to ensure trial validity and fairness. Black-box AI models create compliance risk. Our solution provides an explainable audit trail for every decision, linking patient data points to specific trial inclusion/exclusion rules. This demonstrable logic satisfies FDA guidance on computerized systems and provides clear documentation for sponsor audits, reducing regulatory friction. Explore related applications in our pillar on Neuro-symbolic Reasoning and Transparent Decisioning.

Clinical trial sites are resource-constrained. By automating the initial eligibility burden, the AI frees up coordinator time for higher-value tasks like patient consent and relationship management. This improves site satisfaction and retention in long-term studies. The system's clear explanations also reduce training time for new staff and standardize screening quality across multi-site trials, leading to more reliable data.

A lack of transparent, systematic screening can inadvertently exclude diverse patient populations. Our AI applies protocol rules consistently and without bias, ensuring all patients are evaluated against the same objective criteria. By processing data from community hospitals and large academic centers equally, it helps sponsors identify eligible patients across a broader demographic and geographic spectrum, supporting diversity mandates. This aligns with our focus on ethical frameworks, detailed in Ethics, Bias Mitigation, and Fair AI Frameworks.

Delayed trials cost sponsors millions per day in lost revenue. By accelerating enrollment and improving site efficiency, this AI delivers a clear, measurable return. A typical model shows: Reduced trial timeline by 2-4 months and Lower per-patient screening cost. The investment is justified by faster time-to-market for new therapies and reduced operational burn rate for Contract Research Organizations (CROs).

Each day a trial is delayed costs sponsors an average of $600,000 to $8 million in lost potential revenue. Accelerating recruitment has a direct, massive ROI. A mid-sized biotech used our system for a Phase III cardiovascular trial, cutting the recruitment timeline by 5 months. This translated to an estimated $37M in accelerated revenue and saved over $2M in operational costs from extended site fees and monitoring. The AI investment paid for itself in the first quarter of deployment.

Regulators (FDA, EMA) demand clarity on how patients are selected. Black-box AI creates compliance risk. Our neuro-symbolic approach generates an audit trail for every decision, linking patient data points to specific trial protocol logic. This defensible documentation is critical for regulatory submissions. A sponsor in the neurology space used these explainable reports to successfully pass a FDA audit of their patient recruitment process without findings, mitigating significant regulatory risk.

Up to 80% of relevant patient data resides in unstructured physician notes, inaccessible to traditional matching tools. Our AI uses natural language understanding to extract key concepts like prior treatments, disease progression, and family history. A major academic medical center applied this to their EHR, identifying 3x more potentially eligible patients for rare disease trials than their previous SQL-based system, dramatically improving recruitment feasibility for niche studies.